• head_banner_01

Factory Supply Favipiravir - Impurities of Amino Acid Used for Synthesize Protein – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

Assume full accountability to fulfill all demands of our purchasers; attain continual advancements by marketing the advancement of our clientele; grow to be the final permanent cooperative partner of purchasers and maximize the interests of purchasers for Powder Anticancer Afatinib, Natrium Acetate, Desmopressin Acetate Uses, Any needs from you'll be paid out with our best notice!
Factory Supply Favipiravir - Impurities of Amino Acid Used for Synthesize Protein – Gentolex Detail:

Product Detail

NO

Products

CAS No

Key Quality Indicator

Purity

Max.

impurity

Total solvent residue

Moisture

1

Fmoc-β-Ala-Ala-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

2

Fmoc-D-Ala-D-Ala-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

3

Fmoc-β-Ala-D-Ala-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

4

Fmoc-Arg(pbf)-Arg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

5

Fmoc-β-Ala-Arg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

6

Fmoc-D-Arg(pbf)-D-Arg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

7

Fmoc-β-Ala-D-Arg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

8

Fmoc-HomoArg(pbf)-HomoArg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

9

Fmoc-β-Ala-HomoArg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

10

Fmoc-Asn(Trt)-Asn(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

11

Fmoc-β-Ala-Asn(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

12

Fmoc-Asp(OtBu)-Asp(OtBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

13

Fmoc-β-Ala-Asp(OtBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

14

Fmoc-Cys(Trt)-Cys(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

15

Fmoc-β-Ala-Cys(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

16

Fmoc-Cys(Acm)-Cys(Acm)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

17

Fmoc-β-Ala-Cys(Acm)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

18

Fmoc-Gln(Trt)-Gln(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

19

Fmoc-β-Ala-Gln(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

20

Fmoc-Glu(OtBu)-Glu(OtBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

21

Fmoc-β-Ala-Glu(OtBu)-OH.H2O

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

22

Fmoc-β-Ala-Gly-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

23

Fmoc-His(Trt)-His(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

24

Fmoc-β-Ala-His(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

25

Fmoc-Ile-Ile-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

26

Fmoc-β-Ala-Ile-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

27

Fmoc-Leu-Leu-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

28

Fmoc-β-Ala-Leu-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

29

Fmoc-D-Leu-D-Leu-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

30

Fmoc-β-Ala-D-Leu-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

31

Fmoc-Lys(Boc)-Lys(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

32

Fmoc-β-Ala-Lys(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

33

Fmoc-Lys(Alloc)-Lys(Alloc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

34

Fmoc-β-Ala-Lys(Alloc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

35

Fmoc-Met-Met-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

36

Fmoc-β-Ala-Met-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

37

Fmoc-Orn(Boc)-Orn(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

38

Fmoc-β-Ala-Orn(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

39

Fmoc-Phe-Phe-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

40

Fmoc-β-Ala-Phe-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

41

Fmoc-D-Phe-D-Phe-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

42

Fmoc-β-Ala-D-Phe-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

43

Fmoc-Pro-Pro-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

44

Fmoc-β-Ala-Pro-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

45

Fmoc-Ser(tBu)-Ser(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

46

Fmoc-β-Ala-Ser(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

47

Fmoc-Ser(Trt)-Ser(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

48

Fmoc-β-Ala-Ser(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

49

Fmoc-Thr(tBu)-Thr(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

50

Fmoc-β-Ala-Thr(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

51

Fmoc-Trp(Boc)-Trp(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

52

Fmoc-β-Ala-Trp(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

53

Fmoc-D-Trp(Boc)-D-Trp(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

54

Fmoc-β-Ala-D-Trp(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

55

Fmoc-Tyr(tBu)-Tyr(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

56

Fmoc-β-Ala-Tyr(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

57

Fmoc-D-Tyr(Et)-D-Tyr(Et)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

58

Fmoc-β-Ala-D-Tyr(Et)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

59

Fmoc-Tyr(Me)-Tyr(Me)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

60

Fmoc-β-Ala-Tyr(Me)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

61

Fmoc-Val-Val-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

62

Fmoc-β-Ala-Val-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

63

Fmoc-D-Cit-D-Cit-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

64

Fmoc-β-Ala-D-Cit-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

65

Fmoc-β-Ala-Dab-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

66

Fmoc-(3-(2-naphthyl)-D-Ala)2-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

67

Fmoc-β-Ala-3-(2-naphthyl)-D-Ala-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

68

Fmoc-(3-(3-pyridinyl)-D-Ala)2-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

69

Fmoc-β-Ala-3-(3-pyridinyl)-D-Ala-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

70

Fmoc-(4-chloro-D-Phe)2-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

71

Fmoc-β-Ala-4-chloro-D-Phe-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

72

Fmoc-(D-4Aph(tBuCbm))2-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

73

Fmoc-β-Ala-D-4Aph(tBuCbm)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

74

Fmoc-Aph(L-Hor)-Aph(L-Hor)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

75

Fmoc-β-Ala-Aph(L-Hor)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

76

Fmoc-Lys(iPr,Boc)-Lys(iPr,Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

77

Fmoc-β-Ala-Lys(iPr,Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

78

Fmoc-β-Ala-AEEA-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

79

Fmoc-Aib-Aib-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

80

Fmoc-β-Ala-Aib-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

81

Fmoc-Arg-OH

91000-69-0

≥98.0%

≤1.0%

≤8.0%

≤2.0%

82

H-Arg(pbf)-OH

200115-86-2

≥98.0%

≤1.0%

≤8.0%

≤2.0%

83

Fmoc-D-Arg-OH

130752-32-8

≥98.0%

≤1.0%

≤8.0%

≤2.0%

84

H-D-Arg(pbf)-OH

200116-81-0

≥98.0%

≤1.0%

≤8.0%

≤2.0%

85

Fmoc-HomoArg-OH.HCl

208174-14-5

≥98.0%

≤1.0%

≤8.0%

≤2.0%

86

H-HomoArg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

87

Fmoc-D-HomoArg-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

88

H-D-HomoArg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

89

Fmoc-Asn-OH

71989-16-7

≥98.0%

≤1.0%

≤8.0%

≤2.0%

90

H-Asn(Trt)-OH

132388-58-0

≥98.0%

≤1.0%

≤8.0%

≤2.0%

91

Fmoc-Asp-OH

119062-05-4

≥98.0%

≤1.0%

≤8.0%

≤2.0%

92

H-Asp(OtBu)-OH

3057-74-7

≥98.0%

≤1.0%

≤8.0%

≤2.0%

93

Fmoc-Cys-OH

135248-89-4

≥98.0%

≤1.0%

≤8.0%

≤2.0%

94

H-Cys(Trt)-OH

2799/7/7

≥98.0%

≤1.0%

≤8.0%

≤2.0%

95

H-Cys(Acm)-OH.HCl

28798-28-9

≥98.0%

≤1.0%

≤8.0%

≤2.0%

96

Fmoc-Gln-OH

71989-20-3

≥98.0%

≤1.0%

≤8.0%

≤2.0%

97

H-Gln(Trt)-OH

102747-84-2

≥98.0%

≤1.0%

≤8.0%

≤2.0%

98

Fmoc-Glu-OH

121343-82-6

≥98.0%

≤1.0%

≤8.0%

≤2.0%

99

H-Glu(OtBu)-OH.H2O

2419-56-9

≥98.0%

≤1.0%

≤8.0%

≤2.0%

100

Fmoc-His-OH

116611-64-4

≥98.0%

≤1.0%

≤8.0%

≤2.0%

101

H-His(Trt)-OH

35146-32-8

≥98.0%

≤1.0%

≤8.0%

≤2.0%

102

Boc-His-OH

17791-52-5

≥98.0%

≤1.0%

≤8.0%

≤2.0%

103

Fmoc-Lys-OH

105047-45-8

≥98.0%

≤1.0%

≤8.0%

≤2.0%

104

H-Lys(Boc)-OH

2418-95-3

≥98.0%

≤1.0%

≤8.0%

≤2.0%

105

H-Lys(Alloc)-OH

6298/3/9

≥98.0%

≤1.0%

≤8.0%

≤2.0%

106

Fmoc-Orn-OH.HCl

201046-57-3

≥98.0%

≤1.0%

≤8.0%

≤2.0%

107

H-Orn(Boc)-OH

13650-49-2

≥98.0%

≤1.0%

≤8.0%

≤2.0%

108

Fmoc-Ser-OH

73724-45-5

≥98.0%

≤1.0%

≤8.0%

≤2.0%

109

H-Ser(tBu)-OH

18822-58-7

≥98.0%

≤1.0%

≤8.0%

≤2.0%

110

H-Ser(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

111

Fmoc-Thr-OH.H2O

73731-37-0

≥98.0%

≤1.0%

≤8.0%

≤2.0%

112

H-Thr(tBu)-OH

4378-13-6

≥98.0%

≤1.0%

≤8.0%

≤2.0%

113

Fmoc-Trp-OH

35737-15-6

≥98.0%

≤1.0%

≤8.0%

≤2.0%

114

H-Trp(Boc)-OH

146645-63-8

≥98.0%

≤1.0%

≤8.0%

≤2.0%

115

Fmoc-D-Trp-OH

86123-11-7

≥98.0%

≤1.0%

≤8.0%

≤2.0%

116

H-D-Trp(Boc)-OH

201290-11-1

≥98.0%

≤1.0%

≤8.0%

≤2.0%

117

Fmoc-Tyr-OH

92954-90-0

≥98.0%

≤1.0%

≤8.0%

≤2.0%

118

H-Tyr(tBu)-OH

18822-59-8

≥98.0%

≤1.0%

≤8.0%

≤2.0%

119

Fmoc-D-Tyr-OH

112883-29-1

≥98.0%

≤1.0%

≤8.0%

≤2.0%

120

H-D-Tyr(Et)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

121

H-Tyr(Me)-OH.HCl

67423-44-3

≥98.0%

≤1.0%

≤8.0%

≤2.0%

122

Fmoc-D-4Aph(Cbm)-OH

324017-22-3

≥98.0%

≤1.0%

≤8.0%

≤2.0%

123

H-D-4Aph(tBuCbm)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

124

Fmoc-Lys(iPr)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

125

H-Lys(iPr,Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

About

Compensation

Gentolex provide great quality products, if any product quality is raised by the client within the required time frame with sufficient evidences, we will provide necessary analysis and evaluation to trigger the procedures of compensations.

Production

The capacities of pharmaceutical products reached tons grade, the capacities of chemical products reach 100tons+ grade, the capabilities are well equipped to serve clients worldwide.

Research and Development

Every year, there is plan set up by the R&D team to develop different new products, when targets set, every member in the team will have to carry on with KPI responsibility and with incentive policy.


Product detail pictures:

Factory Supply Favipiravir - Impurities of Amino Acid Used for Synthesize Protein – Gentolex detail pictures


Related Product Guide:

We're committed to furnishing easy,time-saving and money-saving one-stop purchasing support of consumer for Factory Supply Favipiravir - Impurities of Amino Acid Used for Synthesize Protein – Gentolex , The product will supply to all over the world, such as: San Francisco, Uruguay, Pakistan, Customer's satisfaction is always our quest, creating value for customers is always our duty, a long term mutual-beneficial business relationship is what we are doing for. We are an absolutely reliable partner for yourself in China. Of course, other services, like consulting, can be offered too.
  • The factory workers have a good team spirit, so we received high quality products fast, in addition, the price is also appropriate, this is a very good and reliable Chinese manufacturers.
    5 Stars By Mary from Nigeria - 2018.09.21 11:44
    We have been looking for a professional and responsible supplier, and now we find it.
    5 Stars By Sally from Saudi Arabia - 2017.06.25 12:48
    Write your message here and send it to us